Company: FTII
Filing Date: 2025-02-14
Form Type: S-4
Source: 0001493152-25-006997
Chunk: 192

Company: FutureTech II Acquisition Corp.
Filing Date: 2025-02-14
Form: S-4
Chunk 192
---
 |            |   |     |       |     |           |             |   |     |                                        |            |   |     |       |     |           |             |   |
| Weighted average shares outstanding of non-redeemable  
 Common Stock                                           |     |                                 | 3,510,075 |   |     |           |           - |   |     |             |         |     |       |     |                                        |            |   |     |       |     |           |             |   |     |                                        |            |   |     |       |     |           |             |   |
| Net loss per share attributable to common shareholders 
 – basic and diluted                                    |     |                                 |         - |   |     | $         |       (5.96 | ) |     |             |         |     |       |     |                                        |            |   |     |       |     | $         |       (3.69 | ) |     |                                        |            |   |     |       |     | $         |       (3.89 | ) |
| Weighted average shares outstanding – basic and        
 diluted                                                |     |                                 |         - |   |     |           |   9,217,200 |   |     |             |         |     |       |     |                                        |            |   |     |       |     |           |  15,010,984 |   |     |                                        |            |   |     |       |     |           |  14,231,098 |   |

<div align='center'>The accompanying notes are an integral part of these financial statements.</div>

| 90 |

NOTES TO UNAUDITED PRO FORMA COMBINED
FINANCIAL STATEMENTS

Note 1 — Basis of Presentation

The unaudited
pro forma condensed combined financial statements are prepared in accordance with Article 11 of SEC Regulation S-X, as amended January
1, 2021. The historical financial information has been adjusted to give effect to the events that are (i) directly attributable to the
Target Acquisitions and Business Combination and (ii) factually supportable. The historical financial information of Aegeria, Cerevast,
FutureTech, Longevity is presented in accordance with U.S. GAAP.

The acquisition
accounting adjustments relating to both the Target Acquisitions and Business Combination are preliminary and subject to change, as additional
information becomes available and as additional analyses are performed. The